Esperion Starts Next Phase Of Cholesterol Drug TrialThe Plymouth pharma startup Esperion Therapeutics Inc. (Nasdaq: ESPR), Wednesday announced the first patient in a Phase 2b clinical study had received the first dose of ETC-1002, its lead anti-cholesterol drug.
Esperion Therapeutics Reports Financial Details, Corporate UpdateEsperion Therapeutics Inc. (Nasdaq: ESPR), an early-stage pharmaceutical company developing a new class of cholesterol-fighting drugs, Monday provided financial figures and a corporate update.
Esperion Gets $33M To Continue Work On Cholesterol BusterThe Ann Arbor biotech firm Esperion Therapeutics Inc. announced that it has completed a $33 million preferred stock financing led by new investor Longitude Capital.
Cerenis Appoints Non-Executive Director, CMOCerenis Therapeutics, the pharma company developing new high-density lipoprortein therapies for cardiovascular and metabolic diseases, Tuesday appointed Richard C. Pasternak to the board of directors and John F. Paolini, M.D., as Chief Medical Officer.
Esperion Starts Phase 2 Trial Of Cholesterol Buster